Pulse Biosciences, Inc (PLSE): Price and Financial Metrics
PLSE Price/Volume Stats
Current price | $9.80 | 52-week high | $13.62 |
Prev. close | $10.31 | 52-week low | $2.36 |
Day low | $9.77 | Volume | 68,700 |
Day high | $10.35 | Avg. volume | 183,034 |
50-day MA | $9.19 | Dividend yield | N/A |
200-day MA | $7.27 | Market Cap | 539.79M |
PLSE Stock Price Chart Interactive Chart >
PLSE POWR Grades
- PLSE scores best on the Growth dimension, with a Growth rank ahead of 74.46% of US stocks.
- PLSE's strongest trending metric is Value; it's been moving down over the last 26 weeks.
- PLSE ranks lowest in Value; there it ranks in the 2nd percentile.
PLSE Stock Summary
- PULSE BIOSCIENCES INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 7.89% of US listed stocks.
- With a year-over-year growth in debt of -87.54%, PULSE BIOSCIENCES INC's debt growth rate surpasses merely 1.51% of about US stocks.
- Revenue growth over the past 12 months for PULSE BIOSCIENCES INC comes in at -100.58%, a number that bests merely 0.67% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to PULSE BIOSCIENCES INC, a group of peers worth examining would be SENS, SRZN, SABS, ADVM, and DCPH.
- PLSE's SEC filings can be seen here. And to visit PULSE BIOSCIENCES INC's official web site, go to www.pulsebiosciences.com.
PLSE Valuation Summary
- PLSE's price/sales ratio is -74788.9; this is 1780788.1% lower than that of the median Healthcare stock.
- Over the past 93 months, PLSE's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for PLSE.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
PLSE | 2023-12-29 | -74788.9 | 12.9 | -17.1 | -16.6 |
PLSE | 2023-12-28 | -76988.9 | 13.3 | -17.6 | -17.1 |
PLSE | 2023-12-27 | -78455.6 | 13.5 | -17.9 | -17.5 |
PLSE | 2023-12-26 | -77111.1 | 13.3 | -17.6 | -17.1 |
PLSE | 2023-12-22 | -77355.6 | 13.4 | -17.6 | -17.2 |
PLSE | 2023-12-21 | -73744.4 | 12.7 | -16.8 | -16.3 |
PLSE Growth Metrics
- Its 4 year price growth rate is now at -44.04%.
- Its 5 year net income to common stockholders growth rate is now at -342.03%.
- Its 3 year net income to common stockholders growth rate is now at -59.91%.
The table below shows PLSE's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 1.553 | -51.742 | -64.724 |
2022-06-30 | 2.127 | -54.46 | -60.967 |
2022-03-31 | 1.862 | -58.004 | -62.294 |
2021-12-31 | 1.418 | -54.097 | -63.66 |
2021-09-30 | 0.574 | -50.658 | -61.994 |
2021-06-30 | 0 | -45.857 | -60.608 |
PLSE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PLSE has a Quality Grade of D, ranking ahead of 20.2% of graded US stocks.
- PLSE's asset turnover comes in at 0 -- ranking 171st of 186 Medical Equipment stocks.
- BBLG, SNN, and EYE are the stocks whose asset turnover ratios are most correlated with PLSE.
The table below shows PLSE's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0 | NA | -1.553 |
2021-03-31 | 0 | NA | -1.555 |
2020-12-31 | 0 | NA | -1.854 |
2020-09-30 | 0 | NA | -1.789 |
2020-06-30 | 0 | NA | -1.916 |
2020-03-31 | 0 | NA | -1.617 |
PLSE Price Target
For more insight on analysts targets of PLSE, see our PLSE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $38.00 | Average Broker Recommendation | 1.33 (Strong Buy) |
Pulse Biosciences, Inc (PLSE) Company Bio
Pulse Biosciences, a development stage medical device company, focuses on developing medical technologies based on sub-microsecond pulsed electric field technology to detect and treat skin cancer and enhance wound healing. The company was founded in 2014 and is based in Burlingame, California.
Latest PLSE News From Around the Web
Below are the latest news stories about PULSE BIOSCIENCES INC that investors may wish to consider to help them evaluate PLSE as an investment opportunity.
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac CatheterHAYWARD, Calif., December 20, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter. All patients were successfully discharged by treating physicians. Patients will continue to be monitored and |
Executive Chairman of Pulse Biosciences Robert Duggan Buys More StockPulse Biosciences, Inc. ( NASDAQ:PLSE ) shareholders (or potential shareholders) will be happy to see that the... |
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous ElectrodeHAYWARD, Calif., November 21, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA percutaneous electrode. |
Chief Strategy Officer of Pulse Biosciences Picks Up 24% More StockInvestors who take an interest in Pulse Biosciences, Inc. ( NASDAQ:PLSE ) should definitely note that the Chief... |
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare ConferenceHAYWARD, Calif., November 15, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York. |
PLSE Price Returns
1-mo | 6.75% |
3-mo | -14.78% |
6-mo | 137.86% |
1-year | 227.76% |
3-year | -58.44% |
5-year | -49.59% |
YTD | -19.93% |
2023 | 341.88% |
2022 | -81.30% |
2021 | -37.93% |
2020 | 77.93% |
2019 | 17.02% |
Loading social stream, please wait...